Richard R. Furman, M.D.

Medical Oncology
Richard Furman

Dr. Furman is Director of the CLL Research Center at Weill Cornell Medical College and a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology.  His area of focus is on the development of non-chemotherapeutic approaches to treating CLL, and has played an integral part in the development of ibrutinib and idelalisib.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

 

1.   J. A. Woyach, K. Smucker, L. L. Smith, A. Lozanski, Y. Zhong, A. S. Ruppert, D. Lucas, K. Williams, W. Zhao, L. Rassenti, E. Ghia, T. J. Kipps, R. Mantel, J. Jones, J. Flynn, K. Maddocks, S. O'Brien, R. R. Furman, D. F. James, F. Clow, G. Lozanski, A. J. Johnson and J. C. Byrd. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014. 123(12):1810-7.

2.   J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. Li, S. M. Steggerda, M. Versele, S. S. Dave, J. Zhang, A. S. Yilmaz, S. M. Jaglowski, K. A. Blum, A. Lozanski, G. Lozanski, D. F. James, J. C. Barrientos, P. Lichter, S. Stilgenbauer, J. J. Buggy, B. Y. Chang, A. J. Johnson and J. C. Byrd. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med. 2014.

3.   K. van Besien and R. R. Furman. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014. 55(6):1221-2.

4.   J. Ruan, S. A. Gregory, P. Christos, P. Martin, R. R. Furman, M. Coleman and J. P. Leonard. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clin Lymphoma Myeloma Leuk. 2014. 14(2):107-13.

5.   S. O'Brien, R. R. Furman, S. E. Coutre, J. P. Sharman, J. A. Burger, K. A. Blum, B. Grant, D. A. Richards, M. Coleman, W. G. Wierda, J. A. Jones, W. Zhao, N. A. Heerema, A. J. Johnson, R. Izumi, A. Hamdy, B. Y. Chang, T. Graef, F. Clow, J. J. Buggy, D. F. James and J. C. Byrd. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014. 15(1):48-58.

6.   B. S. Kahl, S. E. Spurgeon, R. R. Furman, I. W. Flinn, S. E. Coutre, J. R. Brown, D. M. Benson, J. C. Byrd, S. Peterman, Y. Cho, A. Yu, W. R. Godfrey and N. D. Wagner-Johnston. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014. 123(22):3398-405.

7.   R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. R. Pettitt, S. Ma, S. Stilgenbauer, P. Cramer, M. Aiello, D. M. Johnson, L. L. Miller, D. Li, T. M. Jahn, R. D. Dansey, M. Hallek and S. M. O'Brien. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014. 370(11):997-1007.

8.   R. R. Furman, S. Cheng, P. Lu, M. Setty, A. R. Perez, A. Guo, J. Racchumi, G. Xu, H. Wu, J. Ma, S. M. Steggerda, M. Coleman, C. Leslie and Y. L. Wang. Ibrutinib Resistance in Chronic Lymphocytic Leukemia. N Engl J Med. 2014.

9.   R. R. Furman, J. C. Byrd and S. M. O'Brien. Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion. Clin Adv Hematol Oncol. 2014. 12(1 Suppl 3):11-3.

10. R. R. Furman. Unmet needs in the treatment of chronic lymphocytic leukemia: introduction. Clin Adv Hematol Oncol. 2014. 12(1 Suppl 3):2-5.

11. I. W. Flinn, B. S. Kahl, J. P. Leonard, R. R. Furman, J. R. Brown, J. C. Byrd, N. D. Wagner-Johnston, S. E. Coutre, D. M. Benson, S. Peterman, Y. Cho, H. K. Webb, D. M. Johnson, A. S. Yu, R. G. Ulrich, W. R. Godfrey, L. L. Miller and S. E. Spurgeon. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014. 123(22):3406-13.

12. R. L. Elstrom, J. Ruan, P. J. Christos, P. Martin, D. Lebovic, J. Osborne, S. Goldsmith, J. Greenberg, R. R. Furman, A. Avram, R. Putman, E. Chapman, M. Mazumdar, K. Griffith, M. Coleman, J. P. Leonard and M. S. Kaminski. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin's lymphoma receiving radioimmunotherapy with I-tositumomab. Leuk Lymphoma. 2014.

13. S. Cheng, J. Ma, A. Guo, P. Lu, J. P. Leonard, M. Coleman, M. Liu, J. J. Buggy, R. R. Furman and Y. L. Wang. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014. 28(3):649-57.

14. J. C. Byrd, J. M. Pagel, F. T. Awan, A. Forero, I. W. Flinn, D. P. Deauna-Limayo, S. E. Spurgeon, L. A. Andritsos, A. K. Gopal, J. P. Leonard, A. J. Eisenfeld, J. E. Bannink, S. C. Stromatt and R. R. Furman. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014. 123(9):1302-8.

15. J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, S. Devereux, P. M. Barr, R. R. Furman, T. J. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris-Cappio, T. Robak, J. Delgado, S. J. Schuster, M. Montillo, A. Schuh, S. de Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, J. J. Jones, A. D. Chu, M. Fardis, J. McGreivy, F. Clow, D. F. James, P. Hillmen and R. I. the. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med. 2014.

16. J. R. Brown, J. C. Byrd, S. E. Coutre, D. M. Benson, I. W. Flinn, N. D. Wagner-Johnston, S. E. Spurgeon, B. S. Kahl, C. Bello, H. K. Webb, D. M. Johnson, S. Peterman, D. Li, T. M. Jahn, B. J. Lannutti, R. G. Ulrich, A. S. Yu, L. L. Miller and R. R. Furman. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014. 123(22):3390-7.

17. C. M. Legendre, C. Licht, P. Muus, L. A. Greenbaum, S. Babu, C. Bedrosian, C. Bingham, D. J. Cohen, Y. Delmas, K. Douglas, F. Eitner, T. Feldkamp, D. Fouque, R. R. Furman, O. Gaber, M. Herthelius, M. Hourmant, D. Karpman, Y. Lebranchu, C. Mariat, J. Menne, B. Moulin, J. Nurnberger, M. Ogawa, G. Remuzzi, T. Richard, R. Sberro-Soussan, B. Severino, N. S. Sheerin, A. Trivelli, L. B. Zimmerhackl, T. Goodship and C. Loirat. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013. 368(23):2169-81.

18. R. Kurzrock, P. M. Voorhees, C. Casper, R. R. Furman, L. Fayad, S. Lonial, H. Borghaei, S. Jagannath, L. Sokol, S. Z. Usmani, H. van de Velde, X. Qin, T. A. Puchalski, B. Hall, M. Reddy, M. Qi and F. van Rhee. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013. 19(13):3659-70.

19. J. A. Dubovsky, K. A. Beckwith, G. Natarajan, J. A. Woyach, S. Jaglowski, Y. Zhong, J. D. Hessler, T. M. Liu, B. Y. Chang, K. M. Larkin, M. R. Stefanovski, D. L. Chappell, F. W. Frissora, L. L. Smith, K. A. Smucker, J. M. Flynn, J. A. Jones, L. A. Andritsos, K. Maddocks, A. M. Lehman, R. Furman, J. Sharman, A. Mishra, M. A. Caligiuri, A. R. Satoskar, J. J. Buggy, N. Muthusamy, A. J. Johnson and J. C. Byrd. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013. 122(15):2539-49.

20. K. S. Chitta, A. Paulus, S. Ailawadhi, B. A. Foster, M. T. Moser, P. Starostik, A. Masood, T. Sher, K. C. Miller, D. M. Iancu, J. Conroy, N. J. Nowak, S. N. Sait, D. A. Personett, M. Coleman, R. R. Furman, P. Martin, S. M. Ansell, K. Lee and A. A. Chanan-Khan. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013. 54(2):387-96.

21. J. C. Byrd, R. R. Furman, S. E. Coutre, I. W. Flinn, J. A. Burger, K. A. Blum, B. Grant, J. P. Sharman, M. Coleman, W. G. Wierda, J. A. Jones, W. Zhao, N. A. Heerema, A. J. Johnson, J. Sukbuntherng, B. Y. Chang, F. Clow, E. Hedrick, J. J. Buggy, D. F. James and S. O'Brien. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013. 369(1):32-42.

22. R. H. Advani, J. J. Buggy, J. P. Sharman, S. M. Smith, T. E. Boyd, B. Grant, K. S. Kolibaba, R. R. Furman, S. Rodriguez, B. Y. Chang, J. Sukbuntherng, R. Izumi, A. Hamdy, E. Hedrick and N. H. Fowler. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013. 31(1):88-94.

23. C. M. Wendtner, P. Hillmen, D. Mahadevan, A. Buhler, L. Uharek, S. Coutre, O. Frankfurt, A. Bloor, F. Bosch, R. R. Furman, E. Kimby, J. G. Gribben, M. Gobbi, L. Dreisbach, D. D. Hurd, M. A. Sekeres, A. Ferrajoli, S. Shah, J. Zhang, L. Moutouh-de Parseval, M. Hallek, N. A. Heerema, S. Stilgenbauer and A. A. Chanan-Khan. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012. 53(3):417-23.

24. P. Gupta, D. M. Goldenberg, E. A. Rossi, T. M. Cardillo, J. C. Byrd, N. Muthusamy, R. R. Furman and C. H. Chang. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 2012. 119(16):3767-78.

25. C. T. C. Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica. 2012. 97(3):428-36.

26. F. Foss, S. M. Horwitz, B. Coiffier, N. Bartlett, L. Popplewell, B. Pro, L. C. Pinter-Brown, A. Shustov, R. R. Furman, C. Haioun, T. Koutsoukos and O. A. O'Connor. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012. 12(4):238-43.

27. R. L. Elstrom, P. Martin, S. Hurtado Rua, T. B. Shore, R. R. Furman, J. Ruan, R. N. Pearse, M. Coleman, T. Mark, J. P. Leonard and U. Gergis. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012. 87(4):433-5.

28. R. L. Elstrom, B. Andemariam, P. Martin, J. Ruan, T. B. Shore, M. Coleman, J. P. Leonard and R. R. Furman. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012. 53(8):1469-73.

29. M. Cols, C. M. Barra, B. He, I. Puga, W. Xu, A. Chiu, W. Tam, D. M. Knowles, S. R. Dillon, J. P. Leonard, R. R. Furman, K. Chen and A. Cerutti. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012. 188(12):6071-83.

30. M. Alsina, S. Trudel, R. R. Furman, P. J. Rosen, O. A. O'Connor, R. L. Comenzo, A. Wong, L. A. Kunkel, C. J. Molineaux and A. Goy. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012. 18(17):4830-40.

31. J. Ruan, P. Martin, R. R. Furman, S. M. Lee, K. Cheung, J. M. Vose, A. Lacasce, J. Morrison, R. Elstrom, S. Ely, A. Chadburn, E. Cesarman, M. Coleman and J. P. Leonard. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011. 29(6):690-7.

32. D. Pulte, R. R. Furman, M. J. Broekman, J. H. Drosopoulos, H. S. Ballard, K. E. Olson, J. R. Kizer and A. J. Marcus. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011. 11(4):367-72.

33. O. A. O'Connor, B. Pro, L. Pinter-Brown, N. Bartlett, L. Popplewell, B. Coiffier, M. J. Lechowicz, K. J. Savage, A. R. Shustov, C. Gisselbrecht, E. Jacobsen, P. L. Zinzani, R. Furman, A. Goy, C. Haioun, M. Crump, J. M. Zain, E. Hsi, A. Boyd and S. Horwitz. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011. 29(9):1182-9.

34. J. R. Genzen, K. R. Kawaguchi and R. R. Furman. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol. 2011. 155(1):123-5.

35. R. R. Furman, M. L. Grossbard, J. L. Johnson, A. L. Pecora, P. A. Cassileth, S. H. Jung, B. A. Peterson, L. M. Nadler, A. Freedman, R. L. Bayer, N. L. Bartlett, D. D. Hurd, B. D. Cheson, B. Cancer Leukemia Group and G. Eastern Cooperative Oncology. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011. 52(4):587-96.

36. W. G. Wierda, T. J. Kipps, J. Mayer, S. Stilgenbauer, C. D. Williams, A. Hellmann, T. Robak, R. R. Furman, P. Hillmen, M. Trneny, M. J. Dyer, S. Padmanabhan, M. Piotrowska, T. Kozak, G. Chan, R. Davis, N. Losic, J. Wilms, C. A. Russell, A. Osterborg and C. D. S. I. Hx. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010. 28(10):1749-55.

37. F. van Rhee, L. Fayad, P. Voorhees, R. Furman, S. Lonial, H. Borghaei, L. Sokol, J. Crawford, M. Cornfeld, M. Qi, X. Qin, J. Herring, C. Casper and R. Kurzrock. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010. 28(23):3701-8.

38. C. A. Thompson, M. E. Charlson, E. Schenkein, M. T. Wells, R. R. Furman, R. Elstrom, J. Ruan, P. Martin and J. P. Leonard. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010. 21(11):2262-6.

39. R. Stein, P. Gupta, X. Chen, T. M. Cardillo, R. R. Furman, S. Chen, C. H. Chang and D. M. Goldenberg. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010. 115(25):5180-90.

40. Z. Song, P. Lu, R. R. Furman, J. P. Leonard, P. Martin, L. Tyrell, F. Y. Lee, D. M. Knowles, M. Coleman and Y. L. Wang. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res. 2010. 16(2):587-99.

41. J. Ruan, P. Martin, M. Coleman, R. R. Furman, K. Cheung, A. Faye, R. Elstrom, M. Lachs, K. A. Hajjar and J. P. Leonard. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010. 116(11):2655-64.

42. N. C. Panarelli, R. R. Furman, Y. L. Wang, R. Elstrom, J. A. Cohen and A. Chadburn. NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. J Hematop. 2010. 3(1):35-40.

43. C. M. Magro, P. Porcu, J. Schaefer, J. W. Erter, R. R. Furman, P. K. Shitabata and A. N. Crowson. Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol. 2010. 63(2):292-308.

44. R. R. Furman, P. Martin, J. Ruan, Y. K. Cheung, J. M. Vose, A. S. LaCasce, R. Elstrom, M. Coleman and J. P. Leonard. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010. 116(23):5432-9.

45. R. R. Furman, A. Forero-Torres, A. Shustov and J. G. Drachman. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010. 51(2):228-35.

46. R. R. Furman. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010. 2010(77-81.

47. R. R. Furman. New agents in early clinical trials for CLL therapy. Clin Adv Hematol Oncol. 2010. 8(7):475-6.

48. R. L. Elstrom, P. Martin, K. Ostrow, J. Barrientos, A. Chadburn, R. Furman, J. Ruan, T. Shore, M. Schuster, L. Cerchietti, A. Melnick, M. Coleman and J. P. Leonard. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010. 10(3):192-6.

49. P. Martin, J. P. Leonard, M. Coleman and R. R. Furman. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma. 2009. 9(3):247-9.

50. P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. Diliberto, A. Melnick, D. M. Knowles, S. Chen-Kiang, M. Coleman and J. P. Leonard. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009. 27(8):1209-13.

51. J. K. Gordon, C. Magro, T. Lu, R. Schneider, A. Chiu, R. R. Furman, G. Solomon, A. Bass and D. Erkan. Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS J. 2009. 5(2):169-77.

52. C. R. Fraser, W. Wang, M. Gomez, T. Zhang, S. Mathew, R. R. Furman, D. M. Knowles, A. Orazi and W. Tam. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009. 132(6):928-39.

53. K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, R. R. Furman, J. M. Vose, A. D. Zelenetz, R. Mamtani, D. W. Raisch, G. W. Dorshimer, S. T. Rosen, K. Muro, N. R. Gottardi-Littell, R. L. Talley, O. Sartor, D. Green, E. O. Major and C. L. Bennett. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009. 113(20):4834-40.

54. R. Advani, A. Forero-Torres, R. R. Furman, J. D. Rosenblatt, A. Younes, H. Ren, K. Harrop, N. Whiting and J. G. Drachman. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009. 27(26):4371-7.

55. S. C. Rutherford, B. Andemariam, S. M. Philips, R. L. Elstrom, A. Chadburn, R. R. Furman, R. Niesvizky, P. Martin, T. J. Fahey, M. Coleman, S. J. Goldsmith and J. P. Leonard. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma. 2008. 49(4):719-26.

56. L. Paoluzzi, M. Gonen, G. Bhagat, R. R. Furman, J. R. Gardner, L. Scotto, V. D. Gueorguiev, M. L. Heaney, K. Manova and O. A. O'Connor. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008. 112(7):2906-16.

57. P. Martin, R. R. Furman, J. Ruan, R. Elstrom, J. Barrientos, R. Niesvizky, M. Coleman and J. P. Leonard. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol. 2008. 45(2):126-32.

58. P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, E. J. Feldman, T. B. Shore, M. W. Schuster, S. Ely, D. M. Knowles, S. Chen-Kiang, M. Coleman and J. P. Leonard. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008. 19(7):1327-30.

59. T. Mark, D. Jayabalan, M. Coleman, R. N. Pearse, Y. L. Wang, R. Lent, P. J. Christos, J. W. Lee, Y. P. Agrawal, S. Matthew, S. Ely, M. Mazumdar, E. Cesarman, J. P. Leonard, R. R. Furman, S. Chen-Kiang and R. Niesvizky. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008. 143(5):654-60.

60. J. P. Leonard, P. Martin, J. Ruan, R. Elstrom, J. Barrientos, M. Coleman and R. R. Furman. New monoclonal antibodies for non-Hodgkin's lymphoma. Ann Oncol. 2008. 19 Suppl 4(iv60-2.

61. P. J. Krause, B. E. Gewurz, D. Hill, F. M. Marty, E. Vannier, I. M. Foppa, R. R. Furman, E. Neuhaus, G. Skowron, S. Gupta, C. McCalla, E. L. Pesanti, M. Young, D. Heiman, G. Hsue, J. A. Gelfand, G. P. Wormser, J. Dickason, F. J. Bia, B. Hartman, S. R. Telford, 3rd, D. Christianson, K. Dardick, M. Coleman, J. E. Girotto and A. Spielman. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008. 46(3):370-6.

62. M. Coleman, P. Martin, J. Ruan, R. Furman, R. Niesvizky, R. Elstrom, P. George, J. Leonard and T. Kaufmann. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008. 49(3):447-50.

63. M. Coleman, P. Martin, J. Ruan, R. Furman, R. Niesvizky, R. Elstrom, P. George, T. P. Kaufman and J. P. Leonard. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008. 112(10):2228-32.

64. V. S. Blinder, A. Chadburn, R. R. Furman, S. Mathew and J. P. Leonard. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS. 2008. 22(3):175-87.

65. G. J. Roboz, J. M. Bennett, M. Coleman, E. K. Ritchie, R. R. Furman, A. Rossi, K. Jhaveri, E. J. Feldman and J. P. Leonard. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res. 2007. 31(8):1141-4.

66. D. Pulte, K. E. Olson, M. J. Broekman, N. Islam, H. S. Ballard, R. R. Furman, A. E. Olson and A. J. Marcus. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med. 2007. 5(23.

67. J. V. Mones, M. Coleman, L. Kostakoglu, R. R. Furman, A. Chadburn, T. B. Shore, D. Muss, P. Stewart, S. Kroll, S. Vallabhajosula, S. J. Goldsmith and J. P. Leonard. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma. 2007. 48(2):342-8.

68. P. Martin, R. R. Furman, M. Coleman and J. P. Leonard. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin Cancer Res. 2007. 13(18 Pt 2):5636s-5642s.

69. R. R. Furman and J. P. Leonard. Immunotherapy of B-cell malignancies: first MABs, now SMIPs. Blood. 2007. 110(7):2218.

70. R. R. Furman and D. Hoelzer. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Semin Oncol. 2007. 34(6 Suppl 5):S29-34.

71. J. P. Leonard, R. R. Furman and M. Coleman. Targeting proteasome inhibition in lymphoma and other lymphoproliferative disorders. The American Journal of Oncology Review. 2006. 5(4(Suppl6)):11-14.

72. J. P. Leonard, R. R. Furman and M. Coleman. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer. 2006. 119(5):971-9.

73. L. Kostakoglu, S. J. Goldsmith, J. P. Leonard, P. Christos, R. R. Furman, T. Atasever, A. Chandramouly, S. Verma, P. Kothari and M. Coleman. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006. 107(11):2678-87.

74. R. R. Furman, M. Coleman, D. Muss and J. P. Leonard. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer Treat Res. 2006. 131(221-50.

75. A. D. Dosik, M. Coleman, L. Kostakoglu, R. R. Furman, J. M. Fiore, D. Muss, R. Niesvizky, T. Shore, M. W. Schuster, P. Stewart, S. Vallabhajosula, S. J. Goldsmith and J. P. Leonard. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006. 106(3):616-22.

76. J. P. Leonard, R. R. Furman, J. Ruan and M. Coleman. New developments in immunotherapy for non-Hodgkin's lymphoma. Curr Oncol Rep. 2005. 7(5):364-71.

77. J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. R. Furman, M. W. Schuster, R. Niesvizky, D. Muss, J. Fiore, S. Kroll, G. Tidmarsh, S. Vallabhajosula and S. J. Goldsmith. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005. 23(24):5696-704.

78. J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, J. Kovacs, C. L. Ding, W. A. Wegener, I. D. Horak and D. M. Goldenberg. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005. 23(22):5044-51.

79. J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, U. Gayko, S. Z. Fields, A. Cesano and D. M. Goldenberg. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004. 10(16):5327-34.

80. R. R. Furman, M. Coleman and J. P. Leonard. Epratuzumab in non-Hodgkin's lymphomas. Curr Treat Options Oncol. 2004. 5(4):283-8.

81. J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, U. Gayko, A. Cesano and D. M. Goldenberg. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003. 21(16):3051-9.

82. G. Damaj, F. Lefrere, R. Delarue, B. Varet, R. Furman and O. Hermine. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003. 17(9):1914-5.

83. R. R. Furman, Z. Asgary, J. O. Mascarenhas, H. C. Liou and E. J. Schattner. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000. 164(4):2200-6.

 

Book Chapters:

  1. RR Furman, JP Leonard, J Decter, M Coleman. Monoclonal antibodies in lymphomas. In Apoptosis and Senescence in Cancer Chemotherapy and Radiotherapy; ed. David A. Gewirtz, Humana Press, 2007.
  2. EJ Schattner, RR Furman, A Bernal. NF-kB in human cancers. In NF-kB / Rel Transcription Factor Family; ed. Hsiou-Chi Liou, Springer, 2006.
  3. M Coleman, RR Furman, J Decter, WA Wegener, ID Horak, DM Goldenberg, JP Leonard.  Epratuzumab: A new humanised monoclonal antibody to CD22. In Therapeutic Strategies in Lymphoid Malignancies; ed. Peter Hillmen and Thomas E. Witzig, Clinical Publishing, 2005.

 

 

Honors and Awards

Charles, Lillian and Betty Neuwirth Clinical Scholar Award, 2004-2006